Scientists at The Scripps Research Institute (TSRI) have achieved a major milestone toward designing a safe and effective vaccine to both treat heroin addiction and block lethal overdose of the drug.
Their research, published today in the journal Molecular Pharmaceutics, shows how a new anti-heroin formulation that is safe in animal models remains stable at room temperature for at least 30 days. As a result, the vaccine is close to being ready for human testing.
“The heroin vaccine is one step closer to clinical evaluation,” says Candy S. Hwang, PhD, first author of the study and a research associate at TSRI.
According to the National Institute on Drug Abuse, 15,446 Americans died from heroin overdose between 2000 and 2016, and the mortality rates are increasing. Heroin abuse has been further fueled by a rise in prescription opioid abuse—studies show that opioid pain reliever users are 40 times more likely to abuse heroin.
The first formulation of the heroin vaccine was developed in 2013 by a team led by Kim D. Janda, PhD, the Ely R. Callaway Jr. Professor of Chemistry and member of the Skaggs Institute for Chemical Biology at TSRI. It has been shown to be effective—and safe—in both mouse and non-human primate models.
The vaccine works by training the immune system antibodies to recognize and bind to heroin molecules, blocking the drug from reaching the brain to cause a “high.” Researchers believe that blocking the high of heroin will help eliminate the motivation for many recovering addicts to relapse into drug use.
The heroin molecule does not naturally prompt an antibody response, so researchers attach it to a carrier protein that alerts the immune system to start making antibodies. Scientists also add an ingredient called an adjuvant to the vaccine, which boosts the immune response and makes the vaccine more effective.
Hwang says, “Our goal was to prepare a vaccine that could be advanced to clinical trials. As such, we were looking for the best combination of ‘hapten’ (the heroin molecule), carrier protein and adjuvant to keep the vaccine both stable for transport and storage but still efficacious.”
For the new study, the researchers investigated how 20 different carrier protein/adjuvant combinations worked, including shelf stability based on temperature and storage time and whether the formulation was a liquid or powder.
Their experiments in rodent models showed that the best vaccine formulation contained a carrier protein called tetanus toxoid (TT) and adjuvants called alum and CpG ODN. The discovery that alum worked best as an adjuvant was especially significant since alum is one of the few adjuvants used in vaccines already approved by the U.S. Food and Drug Administration. The researchers also found that there was no difference in how well it worked between the liquid and powder versions of this formulation.
Hwang notes that the best vaccine formulation showed protection against lethal doses of heroin. This is particularly important as many heroin addicts have succumb to overdose and death during their attempts to quit the drug.
With this new study, the researchers have shown that the vaccine is safe and effective in animal models, stable under clinical conditions and reliant on an already-approved adjuvant. The next step is to find a producer to make the vaccine on a large scale.
“We believe that a heroin vaccine would be tremendously beneficial for people who have a heroin substance use disorder but have found difficulty in trying to quit,” says Hwang.
Learn more: Heroin vaccine blocks lethal overdose
The Latest on: Heroin vaccine
Biotech Announces Encouraging HIV Vaccine Results
on May 23, 2018 at 8:42 am
In a May 16, 2018 research note, analyst Ram Selvaraju with H.C. Wainwright & Co. reported that Inovio Pharmaceuticals Inc. (INO:NASDAQ) HIV vaccine, PENNVAX-GP, "delivers robust and durable immune responses." At the recent HIV Vaccine Trials Network's ... […]
Erectile dysfunction drugs and flu vaccine may help fight cancer after surgery: study
on May 21, 2018 at 7:00 pm
The flu vaccine then further stimulated cancer-killing NK cells. This incredibly simple therapy was found to cut the number of spreading cancer cells by more 90 per cent in lab mice. “(It was) almost like the animal didn’t have surgery at all,” Auer ... […]
Brainstorm Health: Drug Industry Middlemen, Health Care on the Fortune 500, Congo Ebola Vaccine
on May 21, 2018 at 9:45 am
When President Trump spoke on May 11 about his grand plan to lower drug prices, he singled out one particular bad actor with a particularly villainous name: “the middleman.” “We’re very much eliminating the middlemen,” said Trump during his Rose ... […]
Officials working to stop Ebola outbreak in Congo distribute experimental vaccine
on May 21, 2018 at 5:27 am
Authorities will begin distributing an experimental Ebola vaccine in Mbandaka, a major city in the Democratic Republic of Congo, on Monday to try to stop the spread of the deadly virus. Healthcare workers in Mbandaka, the capital of Equateur Province and ... […]
GC Pharma sets up vaccine firm in U.S.
on May 20, 2018 at 5:48 pm
SEOUL, May 21 (Yonhap) -- South Korean drug company GC Pharma set up a vaccine manufacturer, Curevo Inc., in the United States toward the end of last year, industry sources reported for the first time Monday. The Seattle-based company, established in ... […]
Viagra and flu 'drug cocktail' could prevent spread of cancer following surgery
on May 20, 2018 at 7:11 am
A combination of erectile dysfunction drugs and the flu vaccine could prevent the spread of cancer, groundbreaking new research suggests. The study, published in OncuImunnology, showed that this unconventional strategy may be able to help patients ... […]
Erectile Dysfunction Drug, Flu Vaccine May Reduce Cancer Spread
on May 18, 2018 at 1:43 am
Could the unconventional combination of the flu vaccine and erectile dysfunction drugs help the immune system fight cancer cells left behind after surgery? After a mouse study showed promising results, which were published in the journal OncoImmunology ... […]
Health care bill addresses opioids, vaccines and drug take-back programs
on May 15, 2018 at 6:52 pm
JEFFERSON CITY — An omnibus health care bill that would impose limitations on opioids is one step closer to the governor’s desk. The Senate passed SB 826 Tuesday, and the bill will now move back to the House. The bill would make it more difficult to ... […]
New MS Drug May Reduce Effectiveness of Certain Vaccines
on May 9, 2018 at 2:23 pm
Researchers say ocrelizumab may diminish the immune response in people with multiple sclerosis who receive vaccines for tetanus, seasonal flu, and pneumococcus. One year after its approval, experts continue to study the impact of ocrelizumab, the first ... […]
via Google News and Bing News